GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GT Biopharma Inc (NAS:GTBP) » Definitions » 3-Year EPS without NRI Growth Rate

GT Biopharma (GT Biopharma) 3-Year EPS without NRI Growth Rate : 60.50% (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is GT Biopharma 3-Year EPS without NRI Growth Rate?

GT Biopharma's EPS without NRI for the three months ended in Mar. 2024 was $-2.12.

During the past 3 years, the average EPS without NRI Growth Rate was 60.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 49.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 43.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of GT Biopharma was 98.80% per year. The lowest was -364.20% per year. And the median was 30.70% per year.


Competitive Comparison of GT Biopharma's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, GT Biopharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GT Biopharma's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where GT Biopharma's 3-Year EPS without NRI Growth Rate falls into.



GT Biopharma 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


GT Biopharma  (NAS:GTBP) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


GT Biopharma 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of GT Biopharma's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


GT Biopharma (GT Biopharma) Business Description

Industry
Traded in Other Exchanges
Address
8000 Marina Boulevard, Suite 100, Brisbane, CA, USA, 94005
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Executives
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Michael Martin Breen director, officer: Exec. Chair. and Interim CEO LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU
Manu Ohri officer: CFO & Secretary 2355 MAIN STREET, SUITE 120, IRVINE CA 92614
Bruce Wendel director 70 ELEVEN O'CLOCK ROAD, WESTON CT 06883
Gregory Berk officer: Pres. of R&D, CMO HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080
Shrotriya Rajesh C Md director 157 TECHNOLOGY DRIVE, IRVINE CA 92618
Alan Louis Urban director 1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404
Gavin Choy officer: Acting Chief Financial Officer 8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005
Steven W Weldon director, officer: CFO 7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835
Shawn Cross director, officer: Chief Executive Officer 1825 K STREET SUITE 510, WASHINGTON DC 20006
Raymond W. Urbanski officer: Chief Medical Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Kathleen Clarence-smith director, 10 percent owner, officer: CEO 1623 31ST STREET NW, WASHINGTON DC 20007
Mark J Silverman 10 percent owner 224 22ND ST., SANTA MONICA CA 90402
Bristol Capital Llc 10 percent owner
Bristol Investment Fund Ltd 10 percent owner 89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205

GT Biopharma (GT Biopharma) Headlines

From GuruFocus

GT Biopharma Names Charles J. Casamento to the Board of Directors

By sperokesalga sperokesalga 05-04-2023

GT Biopharma Appoints Manu Ohri as Chief Financial Officer

By PRNewswire PRNewswire 02-18-2022

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

By Value_Insider Value_Insider 12-14-2022